ALFA Finder| Revenue growth | 19% YoY for FY26; ₹4,316 million total revenue. |
|---|---|
| Margins | Gross margin normalized to 56% from elevated 63% in FY25. |
| Demand visibility | Strong for flagship hybrids Sanket and Jumbo; maize growing rapidly. |
| Management confidence | High; focusing on 'under-commit and over-perform' strategy. |
Growth
Revenue grew 19% YoY; PAT stood at ₹384M (9% margin). Cotton-paddy portfolio contributed 58% of revenue.
Outlook
FY27 revenue guidance of 15-20% growth. Targeted international revenue share of 10-15% within five years.
Risks
Erratic monsoons (El Nino) and China export restrictions impacting plant nutrition segment (-18%).
Earnings Call filed with BSE, NSE: NATHBIOGEN. Summary written with AI assistance from the document.
Nath Bio-Genes (India) Ltd: key numbers
- Share price
- ₹140.13
- Market cap
- ₹266.3 Cr
- Revenue (annual)
- ₹445.1 Cr
- Net profit (annual)
- ₹41.63 Cr
- P/E (TTM)
- 7.3×Sector 29.0×
- Promoter holding
- 45.60%+0.00% QoQ
- FII holding
- 0.18%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nath Bio-Genes (India) Ltd
All →Nath Bio-Genes (India) Board Meeting Date
Nath Bio-Genes will hold a board meeting on 14 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The trading window reopens on 17 November 2026.
Nath Bio-Genes (India) Other Announcement
Nath Bio-Genes (India) Limited filed the Compliance Certificate for the quarter ended September 30, 2026, as required under Regulation 74(5) of the SEBI regulations.
Nath Bio-Genes (India) Annual General Meeting
Nath Bio-Genes (India) Ltd held its 33rd AGM on September 24, 2026. Shareholders approved all five resolutions, including a final dividend of ₹2/- per share.
Nath Bio-Genes (India) Annual General Meeting
Nath Bio-Genes (India) Ltd issued notice for its 33rd Annual General Meeting, to be held on September 24, 2026, alongside the Annual Report for FY2025-26.
Nath Bio-Genes (India) ED Probe / Tax Survey
SEBI has initiated a forensic audit of Nath Bio-Genes (India) Ltd for financial years 2020-21 to 2025-26. CNK & Associates LLP has been appointed as the forensic auditor.
- Execution
- FY 2020-21 to 2025-26
Nath Bio-Genes (India) Investor Presentation: Key Takeaways
Nath Bio-Genes reported strong Q1 FY27 results with Revenue and EBITDA growing 15% and 17% YoY respectively. The company continues to focus on high-yield cotton, maize, and paddy seeds.